JACKSONVILLE, Fla. – Academy of Physicians in Clinical Research (APCR) released the below statement on Tuesday following the President’s announcement last Friday regarding prescription drug costs.
As an independent physician organization committed to improving public health, APCR supports and commends the administration for releasing a comprehensive plan to address prescription drug costs. Our organization has actively assessed and engaged on this crucial issue, including hosting a town hall meeting at our annual 2017 conference to explore concepts that could assist patients in need of costly medications.
We applaud the administration’s efforts to encourage broader supply chain transparency and ensure that consumers benefit from rebates negotiated between biopharmaceutical companies, pharmacy benefit managers (PBMs) and health insurance plans. We also believe in encouraging cost effectiveness research. By increasing the emphasis on identifying patients most likely to benefit from specific treatments, clinicians, payers and manufacturers will all better understand how to best deploy breakthrough therapies for the greatest benefit per dollar spent.
We look forward to engaging with the administration during the implementation of the President’s blueprint. We believe that good public policy can balance the “innovation premium” of new drugs while speeding access to important therapies at affordable prices to as many Americans as possible.
Michael Koren, MD, FAPCR, CPI
Academy of Physicians in Clinical Research